212 related articles for article (PubMed ID: 18642670)
1. A natural human IgM antibody that neutralizes botulinum neurotoxin in vivo.
Adekar SP; Al-Saleem FH; Elias MD; Rybinski KA; Simpson LL; Dessain SK
Hybridoma (Larchmt); 2008 Apr; 27(2):65-9. PubMed ID: 18642670
[TBL] [Abstract][Full Text] [Related]
2. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.
Matsumura T; Amatsu S; Misaki R; Yutani M; Du A; Kohda T; Fujiyama K; Ikuta K; Fujinaga Y
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32392791
[TBL] [Abstract][Full Text] [Related]
3. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins.
Adekar SP; Jones RM; Elias MD; Al-Saleem FH; Root MJ; Simpson LL; Dessain SK
J Immunol Methods; 2008 Apr; 333(1-2):156-66. PubMed ID: 18313069
[TBL] [Abstract][Full Text] [Related]
4. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
5. Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Jpn J Infect Dis; 2013; 66(1):46-50. PubMed ID: 23429085
[TBL] [Abstract][Full Text] [Related]
6. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
[TBL] [Abstract][Full Text] [Related]
8. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
Yu Y; Yu J; Li N; Wang S; Yu W; Sun Z
Vaccine; 2009 Oct; 27(44):6148-53. PubMed ID: 19712769
[TBL] [Abstract][Full Text] [Related]
9. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
[TBL] [Abstract][Full Text] [Related]
10. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.
Derman Y; Selby K; Miethe S; Frenzel A; Liu Y; Rasetti-Escargueil C; Avril A; Pelat T; Urbain R; Fontayne A; Thullier P; Sesardic D; Lindström M; Hust M; Korkeala H
Toxins (Basel); 2016 Sep; 8(9):. PubMed ID: 27626446
[TBL] [Abstract][Full Text] [Related]
12. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
13. A human monoclonal antibody that binds serotype A botulinum neurotoxin.
Adekar SP; Jones RM; Elias MD; Al-Saleem FH; Root MJ; Simpson LL; Dessain SK
Hybridoma (Larchmt); 2008 Feb; 27(1):11-7. PubMed ID: 18294071
[TBL] [Abstract][Full Text] [Related]
14. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
Khouri JM; Motter RN; Arnon SS
Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
[TBL] [Abstract][Full Text] [Related]
16. Vaccines against botulism.
Karalewitz AP; Barbieri JT
Curr Opin Microbiol; 2012 Jun; 15(3):317-24. PubMed ID: 22694934
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
[TBL] [Abstract][Full Text] [Related]
18. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
Tremblay JM; Vazquez-Cintron E; Lam KH; Mukherjee J; Bedenice D; Ondeck CA; Conroy MT; Bodt SML; Winner BM; Webb RP; Ichtchenko K; Jin R; McNutt PM; Shoemaker CB
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987745
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
[TBL] [Abstract][Full Text] [Related]
20. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.
Fan Y; Garcia-Rodriguez C; Lou J; Wen W; Conrad F; Zhai W; Smith TJ; Smith LA; Marks JD
PLoS One; 2017; 12(3):e0174187. PubMed ID: 28323873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
